BR9610929A - Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células - Google Patents

Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células

Info

Publication number
BR9610929A
BR9610929A BR9610929-7A BR9610929A BR9610929A BR 9610929 A BR9610929 A BR 9610929A BR 9610929 A BR9610929 A BR 9610929A BR 9610929 A BR9610929 A BR 9610929A
Authority
BR
Brazil
Prior art keywords
cells
infection
immune response
regulate
antigens
Prior art date
Application number
BR9610929-7A
Other languages
English (en)
Inventor
Lothar Steidler
Erik Remaut
Jeremy Mark Wells
Richard William Falla Le Page
Original Assignee
Univ Cambridge Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cambridge Tech filed Critical Univ Cambridge Tech
Publication of BR9610929A publication Critical patent/BR9610929A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

"PROCESSOS PARA LIBERAR UM OU MAIS POLIPEPTìDEOS BIOLOGICAMENTE ATIVOS, E UM OU MAIS ANTìGENOS, PARA REGULAR AS FUNçõES DE SOBREVIVêNCIA, CRESCIMENTO, DIFERENCIAçãO, EFETUADORA OU SUSCETIBILIDADE A INFECçãO DE CéLULAS OU TECIDOS, PARA REFORçAR UMA RESPOSTA IMUNE CONTRA CéLULAS DE TUMOR OU UMA INFECçãO COLONIZANDO UMA SUPERFìCIE MUCOSAL OU TECIDO DISTANTE OU ADJACENTE, PARA MODULAR O TIPO DE RESPOSTA IMUNE (ANTICORPO VERSUS MEDIADA POR CéLULA) CONTRA UM AGENTE INFECCIOSO PATOGêNICO, PARA INDUZIR A APOPTOSE EM CéLULAS DE TUMOR, PARA REGULAR UMA RESPOSTA IMUNE, PARA TRATAR UM ESTADO DOENTIO DESREGULATIVO AUTOIMUNE ALéRGICO OU OUTRO IMUNE, PARA PRODUZIR UMA FORMULAçãO FARMACêUTICA E PARA GERAR UMA BACTéRIA, FORMULAçãO FARMACêUTICA, áCIDO NUCLEICO, USO DO MESMO, BACTéRIA NãO INVASIVA OU NãO PATOGêNICA, E, USO DA MESMA". Processos para liberar polipeptídeos biologicamente ativos e/ou antígenos, junto com dispositivo de liberação e formulações farmacêuticas compreendendo estes dispositivos de liberação.
BR9610929-7A 1995-10-20 1996-10-21 Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células BR9610929A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521568.7A GB9521568D0 (en) 1995-10-20 1995-10-20 Delivery of biologically active polypeptides
PCT/GB1996/002580 WO1997014806A2 (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides

Publications (1)

Publication Number Publication Date
BR9610929A true BR9610929A (pt) 1999-12-21

Family

ID=10782670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610929-7A BR9610929A (pt) 1995-10-20 1996-10-21 Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células

Country Status (17)

Country Link
US (2) US6605286B2 (pt)
EP (1) EP0871748B1 (pt)
JP (2) JP2000508162A (pt)
KR (1) KR19990064308A (pt)
CN (1) CN1195860C (pt)
AT (1) ATE435294T1 (pt)
AU (1) AU7315496A (pt)
BR (1) BR9610929A (pt)
CA (1) CA2234941C (pt)
DE (1) DE69637961D1 (pt)
DK (1) DK0871748T3 (pt)
ES (1) ES2328751T3 (pt)
GB (1) GB9521568D0 (pt)
NO (1) NO328224B1 (pt)
NZ (1) NZ320418A (pt)
WO (1) WO1997014806A2 (pt)
ZA (1) ZA968806B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
CA2297786C (en) * 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
NZ503376A (en) 1997-09-10 2002-10-25 Vion Pharmaceuticals Inc Genetically modified Salmonella sp having a modified msbB gene useful for treating tumours
AU770726B2 (en) 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
FR2791998B1 (fr) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech Lactocoques modifies exprimant une catalase et leurs utilisations
EP1194554B1 (en) * 1999-07-05 2006-10-18 Vlaams Interuniversitair Instituut voor Biotechnologie Delivery of trefoil peptides
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CA2442004A1 (en) * 2001-03-23 2002-10-03 David J. Kyle Microbial feeds for aquaculture and agriculture
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DE60319822T2 (de) 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
EP1514183A2 (en) * 2002-06-20 2005-03-16 BRITISH TELECOMMUNICATIONS public limited company Distributed computer
US20050129711A1 (en) * 2002-11-14 2005-06-16 Janakiraman Ramachandran Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
GB0230331D0 (en) * 2002-12-31 2003-02-05 British Telecomm Method and apparatus for operating a computer network
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4545151B2 (ja) * 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
AU2004224425B2 (en) * 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP5010280B2 (ja) * 2003-02-21 2012-08-29 ハスミ エルエルシー（ディービーエイ シューコーカイ インターナショナル） ヒトリンパ球由来のワクチンアジュバント
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
GB0412655D0 (en) * 2004-06-07 2004-07-07 British Telecomm Distributed storage network
EP1789529B1 (en) 2004-08-20 2013-10-02 Actogenix N.V. Method to improve lactococcus preservation
EP1786445B1 (en) 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Live microbial microbicides
DK1784220T3 (en) 2004-08-26 2018-03-19 Univ Western Ontario BACTERIAL OBJECTIVES TO ACHIEVE IRON
WO2006113475A2 (en) 2005-04-15 2006-10-26 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
JP5049973B2 (ja) * 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌
US8066987B2 (en) * 2005-08-30 2011-11-29 Commonwealth Scientific And Industrial Research Organisation Bacterial delivery of biologically active polypeptides
RU2420569C2 (ru) 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20110183319A1 (en) * 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
AU2007247137A1 (en) 2006-05-02 2007-11-15 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
KR101557509B1 (ko) 2007-01-12 2015-10-06 액토제닉스 엔.브이. 락토코커스 프로모터 및 그것의 용도
EP2774621B1 (en) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
DK3181682T3 (da) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv Reduceret kolonisering af mikrober på slimhinden
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
DK2424972T3 (da) 2009-04-30 2013-10-14 Actogenix Nv Kryobeskyttende midler til frysetørring af mælkesyrebakterier
EP2275527A1 (en) 2009-07-17 2011-01-19 ActoGeniX NV Animal component-free culture medium for bacterial fermentation
EP2483409B1 (en) 2009-09-29 2017-03-22 Intrexon Actobiotics NV LACTOBACILLUS glyceraldehyde-3-phosphate dehydrogenase PROMOTERS AND USES THEREOF
EP2343319A1 (en) 2010-01-07 2011-07-13 University of Ljubljana Genetically modified food grade microorganism for treatment of inflammatory bowel disease
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
JP2013530187A (ja) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
CN101921725B (zh) * 2010-07-27 2013-06-05 浙江大学 一种口服免疫阻断鸡生长抑素作用的转化子及其应用
JP5991650B2 (ja) * 2010-08-10 2016-09-14 国立研究開発法人農業・食品産業技術総合研究機構 サイトカインを発現する豚丹毒菌及び豚丹毒菌を用いたサイトカインのデリバリー方法
RU2766157C2 (ru) 2011-06-01 2022-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
DK2758513T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
AU2013299605A1 (en) 2012-08-07 2015-03-26 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014199448A1 (ja) * 2013-06-11 2014-12-18 ハウスウェルネスフーズ株式会社 貪食細胞へ物質を送達する担体
JP2017519823A (ja) 2014-06-17 2017-07-20 トップジェニックス, インク.Topgenix, Inc. Ｕｖ保護用局所製剤
EP3020816A1 (en) * 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
CN104476458B (zh) * 2014-11-14 2016-08-17 中黔电气集团股份有限公司 一种带自动夹紧机构的低压柜骨架组装台
JP6581208B2 (ja) * 2014-12-23 2019-09-25 イリヤ ファーマ エービー 創傷治癒の方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN108883140A (zh) 2016-01-14 2018-11-23 英特瑞克斯顿阿克图比奥帝克斯有限公司 治疗1型糖尿病的组合物和方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102553825B1 (ko) * 2018-05-04 2023-07-13 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
KR102015116B1 (ko) * 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
HRP20240085T1 (hr) * 2019-03-04 2024-03-29 Aurealis Therapeutics AG Prokariotski ekspresijski sustav indukciran kloridom

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
EP0176320B1 (en) * 1984-09-26 1990-07-25 Eli Lilly And Company A method for expression and secretion in bacillus
US5032510A (en) * 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
GB9006400D0 (en) * 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) * 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
WO1992015689A1 (en) * 1991-03-05 1992-09-17 The Wellcome Foundation Limited Expression of recombinant proteins in attenuated bacteria
IL103530A0 (en) * 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
GB2278358B (en) 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5455034A (en) * 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
US5837509A (en) * 1992-12-30 1998-11-17 Bioteknologisk Institut Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
CA2252439C (en) * 1996-04-19 2014-09-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
ATE346931T1 (de) * 1997-06-20 2006-12-15 Intervet Int Bv Clostridium perfringens impfstoff
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
ES2336647T3 (es) * 2000-10-20 2010-04-15 Bioneer A/S Metodo de fermentacion para la produccion de productos genicos heterologos en bacterias de acido lactico.
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same

Also Published As

Publication number Publication date
GB9521568D0 (en) 1995-12-20
CN1202934A (zh) 1998-12-23
ES2328751T3 (es) 2009-11-17
JP2000508162A (ja) 2000-07-04
US20010006642A1 (en) 2001-07-05
CA2234941A1 (en) 1997-04-24
NZ320418A (en) 2000-03-27
EP0871748B1 (en) 2009-07-01
AU7315496A (en) 1997-05-07
NO981746D0 (no) 1998-04-17
US20030202991A1 (en) 2003-10-30
JP2008067708A (ja) 2008-03-27
CA2234941C (en) 2010-09-21
WO1997014806A2 (en) 1997-04-24
EP0871748A2 (en) 1998-10-21
US6605286B2 (en) 2003-08-12
DE69637961D1 (de) 2009-08-13
MX9803093A (es) 1998-11-29
KR19990064308A (ko) 1999-07-26
NO328224B1 (no) 2010-01-11
CN1195860C (zh) 2005-04-06
NO981746L (no) 1998-06-22
DK0871748T3 (da) 2009-10-19
ZA968806B (en) 1998-04-20
ATE435294T1 (de) 2009-07-15
WO1997014806A3 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
BR9610929A (pt) Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2257172A1 (en) Dissolvable oxides for biological applications
ATE154515T1 (de) Pharmazeutische formulierungen
GEP20032976B (en) Artificial Peptides Having Surface Activity and Use Thereof in The Preparation of Artificial Surfactant
PE126599A1 (es) Materiales de tela con dos o mas composiciones para el cuidado de la piel colocadas encima y articulos fabricados de esto
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
HK1013084A1 (en) Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
IL93360A (en) Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them
ATE95706T1 (de) Aktives implantat.
DE3688841D1 (de) Schwache interferondosierung fuer die erhoehung der impfstoffwirksamkeit.
NO163776C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazoquinoksaliner.
BRPI0016231B8 (pt) composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo
NO302016B1 (no) Anordning for tilförsel i et legeme av innkapslet biologisk materiale
Lewis‐Jones et al. Cowpox can mimic anthrax
CO4410174A1 (es) Preparaciones farmaceuticas de cefixima
GR3021936T3 (en) Pharmaceutical composition comprising a medicament and a water-swellable polymer
GR3032224T3 (en) Therapeutic agent for threatened abortion.
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
GEP20012489B (en) Use of Natural Human α-Interferon
Kubelka et al. Killing of schistosomula of Schistosoma mansoni by macrophages: induction by T-cell clone-derived lymphokines and interferon-gamma
DE69513635T2 (de) Wässrige zubereitung mit verzögerter wirkstofffreigabe
JP2005035914A (ja) 外用剤組成物

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law